Kiadis Pharma issues new shares to participants in its Exit Participation Plan
Amsterdam, The Netherlands, July 1, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it will issue a total of 338,239 new ordinary shares to the participants in its Exit Participation Plan, which was previously implemented to provide incentives to certain executives and key employees of the Company.
As set forth in the Company’s 2015 Annual Report, the Plan would be effectuated at the end of June 2016. It has now been effectuated, in accordance with its terms, through the issuance for no consideration of 338,239 new Company shares.
The new shares will be admitted to trading on Euronext Amsterdam and Euronext Brussels without a prospectus on the basis of the exemption of section 5:4 (1)(f) of the Dutch Financial Supervision Act (Wet op het financieel toezicht).